Rudolph Felix, Ivannikova Maria, Rudolph Tanja K, Rudolph Volker, Gerçek Muhammed, Friedrichs Kai P
Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany.
Front Cardiovasc Med. 2024 Aug 9;11:1447411. doi: 10.3389/fcvm.2024.1447411. eCollection 2024.
We provide an overview about the current landscape of transcatheter tricuspid valve interventions (TTVI) and summarize recent findings from trials including TRILUMINATE, TRILUMINATE Pivotal, bRIGHT, TRICLASP, TRISCEND, TRISCEND II, TRICUS, and Cardioband TR EFS. These studies have demonstrated the safety and efficacy of TTVI. Yet, they have failed to show a prognostic benefit over conservative treatment. On the other hand, significant improvements in health status assessments have been observed. Assessment of right ventricular (RV) function prior to tricuspid interventions is crucial, as changes in preload and afterload may lead to RV failure which is associated with a high mortality. Therefore, this review emphasizes the impact of TTVIs on quality of life and explores the influence of RV dysfunction on therapeutic success and prognosis.
我们概述了经导管三尖瓣介入治疗（TTVI）的当前现状，并总结了包括TRILUMINATE、TRILUMINATE关键试验、bRIGHT、TRICLASP、TRISCEND、TRISCEND II、TRICUS和Cardioband TR EFS等试验的最新研究结果。这些研究已证明TTVI的安全性和有效性。然而，它们未能显示出比保守治疗更具预后益处。另一方面，已观察到健康状况评估有显著改善。三尖瓣介入治疗前对右心室（RV）功能的评估至关重要，因为前负荷和后负荷的变化可能导致RV衰竭，而RV衰竭与高死亡率相关。因此，本综述强调了TTVI对生活质量的影响，并探讨了RV功能障碍对治疗成功和预后的影响。
